Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
12.34
+0.51 (4.31%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases.
It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020.
The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Mineralys Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 10, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Jon Congleton |
Contact Details
Address: 150 N. Radnor Chester Rd., Suite F200 Radnor, Pennsylvania 19087 United States | |
| Phone | 888 378 6240 |
| Website | mineralystx.com |
Stock Details
| Ticker Symbol | MLYS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001933414 |
| CUSIP Number | 603170101 |
| ISIN Number | US6031701013 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jon Congleton | Chief Executive Officer and Director |
| Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. | Founder and Executive Chairman |
| Adam Scott Levy | Chief Financial Officer and Secretary |
| Dr. David M. Rodman M.D. | Chief Medical Officer |
| Cindy Berejikian | Executive Vice President of Operations |
| Sarah Foster | Vice President of Human Resources |
| Dr. Robert McKean Ph.D. | Senior Vice President of CMC |
| Danielle Bradbury | Senior Vice President of Quality Assurance |
| Jeffrey N. Fellows | Senior Vice President of Regulatory Affairs |
| Jessica Ibbitson | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 12, 2024 | 144 | Filing |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 6, 2024 | 144 | Filing |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 11, 2024 | 144 | Filing |